Taysha Gene Therapies (TSHA) PT Lowered to $4 at JMP Securities
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street ends higher after Democrats win Congress; data center stocks tumble
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts TSHA Hot Sheet
Price: $4.36 +6.60%
Rating Summary:
18 Buy, 2 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 17 | Down: 28 | New: 13
Rating Summary:
18 Buy, 2 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 17 | Down: 28 | New: 13
Join SI Premium – FREE
JMP Securities analyst Silvan Tuerkcan lowered the price target on Taysha Gene Therapies (NASDAQ: TSHA) to $4.00 (from $6.00) while maintaining a Market Outperform rating.
You May Also Be Interested In
- Pfizer (PFE) PT Raised to $40 at Argus
- SharkNinja (SN) PT Raised to $300 at Jefferies
- Insulet Corporation (PODD) PT Raised to $200 at Jefferies
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
